the efficacy of nintedanib for expression of surfactant protein
| Project/Area Number |
17K09619
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
Otsuka Mitsuo 札幌医科大学, 医学部, 研究員 (10398323)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 弘毅 札幌医科大学, 医学部, 教授 (60231396)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 特発性肺線維症 / SP-A / 抗線維化薬 / サーファクタント蛋白質A / ニンテダニブ / ピルフェニドン / サーファクタント蛋白質 / 内科 |
|---|
| Outline of Final Research Achievements |
Background: We aim to clarify whether serum SP-A, SP-D, and KL-6 reflect therapeutic outcomes of pirfenidone and nintedanib administration in patients with IPF. Methods: We retrospectively investigated patients with IPF who were initiated on pirfenidone or nintedanib administration between January 2014 and June 2018 at our hospital. Changes in clinical parameters and serum SP-A, SP-D, and KL-6 levels were evaluated. Results: Forty-nine patients were included (pirfenidone, 23; nintedanib, 26). Stable group comprised 32 patients, while progression group comprised 17 patients. In the stable group, changes in SP-A and KL-6 from baseline to 3 and 6 months significantly decreased compared with the progression group. Changes in SP-A and SP-D levels showed significant negative correlations with the change in %FVC and %DLco. Conclusions: Serum SP-A has a potential as a biomarker of therapeutic outcomes of anti-fibrotic drugs.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、間質性肺炎の血清バイオマーカーであるSP-Aが、抗線維化薬の効果予測バイオマーカーになりうることが明らかとなった。実臨床で測定可能であるので臨床応用可能である。
|
Report
(4 results)
Research Products
(7 results)
-
-
-
-
-
-
-
[Presentation] Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF2019
Author(s)
113.Yoshikawa T, Otsuka M, Ikeda K, Mori Y, Umeda Y, Nishikiori H, Miyajima S, Takahashi M, Kuronuma K, Chiba H, Takahashi H
Organizer
European Respiratory Society Annual Congress: 2019 September 28-October 2: Madrid, Spain
Related Report
Int'l Joint Research
